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ABSTRACT
Valproic acid is commonly used in the treatment of both focal and generalized epilepsies and is often tolerated well. Valproic acid is usually tolerated 
well, but serious complications, including hepatotoxicity and hyperammonemic encephalopathy, may occur. Here, we report a case of valproic acid-
induced hyperammonemic encephalopathy on concomitant use with lacosamide.
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INTRODUCTION
Valproic acid is a branched-chain carboxylic acid and is mainly used in 
the treatment of epilepsy and bipolar disorder. It is a broad-spectrum 
antiepileptic agent used in the treatment of absence, myoclonic, partial, 
and tonic-clonic seizures [1,2] It is also used to prevent migraine 
headaches. It acts by increasing the availability of gamma-aminobutyric 
acid (GABA), an inhibitory neurotransmitter, to brain neurons or may 
enhance the action of GABA or mimic its action at post-synaptic receptor 
sites [3]. The most common side effects are transient gastrointestinal 
side effects including anorexia, nausea, and vomiting in approximately 
16% of patients. It is usually tolerated well, but serious complications, 
including hepatotoxicity and hyperammonemic encephalopathy, may 
occur. Hyperammonemic encephalopathy is seen rarely, but potentially 
fatal adverse drug reaction to valproic acid [4]. It can occur when using 
valproic acid as monotherapy, but it more commonly occurs when 
using antiepileptics as combination therapy. Prior reports are there 
implicating phenytoin and phenobarbital as contributing to valproic 
acid hyperammonemic encephalopathy, but newer antiepileptic 
agents are less frequently implicated [5]. Lacosamide is used as an 
adjunctive treatment for epilepsy [6]. We present a rare case report of 
valproate toxicity, that is, hyperammonemic encephalopathy induced 
by concomitant lacosamide use for the treatment of status epilepticus.
CASE REPORT
A 23-year-old male patient is a known case of status epilepticus, with 
a history of seizures since neonatal period with normal development 
but not good in academics. He was on carbamazepine 200 mg twice 
daily, valproate 400 mg twice daily, and escitalopram 0.5 mg twice 
daily. He has a baseline seizure frequency of once in every 2 weeks 
with semiology of up rolling of eyes with tonic posturing of upper and 
lower limbs which last less than a minute with post-ictal drowsiness 
of about half and hour. He was brought to the tertiary care teaching 
hospital with 8 episodes of seizure with similar semiology, no regain of 
consciousness between the last 3-4 seizures. On examination, patient’s 
vitals were stable, pupils bilaterally equally reacting to light, moving all 
four limbs, normal reflexes, and flexor plantars. The patient was started 
on continuous electroencephalogram monitoring and it revealed 
epileptiform discharges. The patient was given lacosamide loading dose 
of 200 mg IV over 15 minutes and continued on maintenance dose of 
lacosamide 200 mg 1-0-1, then on next day, his serum ammonia level 
was found to be 120.8 umol/L (normal level: 10-47 umol/L) which 
was managed with l-carnitine. His symptoms resolved later and his 
serum ammonia levels came down. Valproate and lacosamide were 
discontinued and patient recovered fully.
DISCUSSION
Several case reports on valproate-induced hyperammonemia have 
been reported previously but very few reports on lacosamide-
induced valproic acid toxicity were reported in the previous years. 
The patient was having seizure since neonatal period and he was 
on valproic acid since then. He never developed hyperammonemia 
in the past years. Addition of lacosamide seems to have promoted 
this effect because this was the recent medication given to the 
patient. Valproic acid is known to cause carnitine deficiency, which 
can ultimately lead to hyperammonemia as carnitine helps in the 
metabolism and elimination of valproic acid through beta-oxidation 
of fatty acids in the liver [7]. L-carnitine promotes the transport of 
long-chain fatty acids from the cytosol compartment of the muscle 
fiber to the mitochondria, they undergo β-oxidation and produce 
acetyl-CoA [8].
Discontinuation of the drug is the primary treatment of valproic 
acid toxicity. Full recovery is anticipated in most patients [9]. In 
symptomatic patients whose mental status is altered and is not due 
to seizure activity dosage adjustment or discontinuation of valproate 
may be necessary [10]. Mechanism by which lacosamide contributes 
to valproic acid toxicity is unclear, but this possibility should be 
considered in any patient on these antiepileptics who presents with 
altered mental status.
CONCLUSION
Valproic acid toxicity can be induced in the presence of lacosamide 
although it is not commonly seen. Physicians need to be aware of such 
cases; early diagnosis allows prompt withdrawal of the offending drug.
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